Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03695978 · ClinicalTrials.gov registry record
Efficacy, Safety & Utilisation of Nuwiq, Octanate and Wilate in Previously Untreated & Minimally Treated Haemophilia A Patients
A clinical trial of Haemophilia A, sponsored by Octapharma.
- Recruiting
- Registry status
- 200
- Enrollment target
- 20
- Study locations
NCT03695978 is a study of Haemophilia A that is actively recruiting participants, run by Octapharma. The registered enrollment target is 200 participants, roughly in line with the 200-participant average among 8 other Haemophilia A trials with a reported enrollment target. The trial reports 20 study locations across 5 states.
The verdict
NCT03695978, a study of Haemophilia A, is actively recruiting participants, sponsored by Octapharma.
- RECRUITING
- Registry status
- 200 participants
- Enrollment target
- 20
- Study locations
Study Summary
International, post-authorisation non-interventional study to evaluate real-life effectiveness, safety and utilisation patterns of Octapharma's FVIII concentrates Nuwiq, Octanate, and Wilate in previously untreated and minimally treated severe haemophilia A patients in routine clinical practice.
Conditions Studied
Study Locations (20)
Other
- CENIDOR - Salta
- Azerbaijan State Advanced Training Institute for Doctors Hematology Department Scientific-Research Center of Hemophilia - Baku
- Republican Scientific Center for Radiation Medicine and Human Ecology - Homyel
- Republican Scientific and Practical Centre of Children Oncology, Hematology and Immunology - Minsk
- Hôpital Universitaire des Enfants Reine Fabiola - Brussels
- Cliniques Universitaires Saint-Luc - Brussels
- Cliniques Universitaires Saint-Luc - Brussels
- Department of Hematology Research Research Transition Facility - Edmonton
- University Hospital Centre Zagreb - Zagreb
- Tallinn Childrenś Hospital Clinic of Paediatric Department of Haematology and Oncology - Tallinn
- CENTRE HOSPITALIER UNIVERSITAIRE de BESANCON - Besançon
- CHRU Tours - Hôpital Trousseau - Chambray-lès-Tours
- Centre Régional de Traitement de l'hémophilie - Le Mans
- Hopital Simone Veil Groupement Hospitalier Eaubonne-Montmorency - Montmorency
- CHU Hotel Dieu, Centre de Traitment de l'Hemophilie - Nantes
- Hôspital Necker Enfants Malades - Paris
Florida
- University of Miami Miller School of Medicine - Miami
Louisiana
- Ochsner Clinic Foundation - New Orleans
Nevada
- Cure 4 The Kids Foundation Children's Specialty Center - Las Vegas
Ontario
- McMaster University, Division of Pediatric Hematology/Oncology Room 3N27 - Hamilton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2018-02-13 |
| Est. Completion | 2030-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03695978
The ClinicalTrials.gov registry entry for NCT03695978 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 200-participant average among 8 other Haemophilia A trials with a reported enrollment target. The listed sponsor is Octapharma, which has 43 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Haemophilia A appearing as the primary indexed condition, and to 0 interventions.
NCT03695978 reports 20 study locations spanning 5 distinct geographic areas - top geographies include Other, Florida, Louisiana.
Frequently Asked Questions
What is clinical trial NCT03695978 about?
NCT03695978 is a clinical study titled "Efficacy, Safety & Utilisation of Nuwiq, Octanate and Wilate in Previously Untreated & Minimally Treated Haemophilia A Patients". International, post-authorisation non-interventional study to evaluate real-life effectiveness, safety and utilisation patterns of Octapharma's FVIII concentrates Nuwiq, Octanate, and Wilate in previously untreated and minimally treated severe haemophilia A patients in routine clinical practice.
What is the current status of trial NCT03695978?
This trial is currently recruiting. The enrollment target is 200 participants. The study started on 2018-02-13. Estimated completion is 2030-06.
What conditions does trial NCT03695978 study?
This clinical trial studies the following conditions: Haemophilia A.
Who is sponsoring clinical trial NCT03695978?
This trial is sponsored by Octapharma, which has 43 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03695978 being conducted?
This trial has 20 study locations across Florida, Louisiana, Nevada, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Haemophilia A
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia A
RECRUITING · Phase 1
-
A Research Study Looking at How Food Intake Affects Inno8 in the Body of Healthy People
RECRUITING · Phase 1
-
A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A (FRONTIER 4)
ACTIVE NOT RECRUITING · Phase 3
-
Safety and Efficacy of Turoctocog Alfa in Previously Treated Male Children With Haemophilia A
COMPLETED · Phase 3
-
Evaluation of Safety and Efficacy, Including Pharmacokinetics, of NNC 0129-0000-1003 When Administered for Treatment and Prophylaxis of Bleeding in Subjects With Haemophilia A
COMPLETED · Phase 3
-
A Study of the Impact of Hemophilia and Its Treatment on Brain Development, Thinking and Behaviour in Children With Hemophilia
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.